Vincerx Pharma, Inc.
VINC
$0.055
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.58M | 12.24M | 11.86M | 12.06M | 13.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.06M | 28.17M | 29.99M | 34.68M | 42.61M |
| Operating Income | -29.06M | -28.17M | -29.99M | -34.68M | -42.61M |
| Income Before Tax | -30.07M | -27.03M | -28.19M | -37.94M | -40.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.07 | -27.03 | -28.19 | -37.94 | -40.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.07M | -27.03M | -28.19M | -37.94M | -40.16M |
| EBIT | -29.06M | -28.17M | -29.99M | -34.68M | -42.61M |
| EBITDA | -29.01M | -28.12M | -29.93M | -34.63M | -42.56M |
| EPS Basic | -21.39 | -22.46 | -25.90 | -35.55 | -37.76 |
| Normalized Basic EPS | -12.70 | -14.03 | -16.19 | -22.22 | -23.60 |
| EPS Diluted | -21.39 | -22.46 | -25.90 | -35.55 | -37.76 |
| Normalized Diluted EPS | -12.70 | -14.03 | -16.19 | -22.22 | -23.60 |
| Average Basic Shares Outstanding | 6.37M | 5.20M | 4.70M | 4.27M | 4.26M |
| Average Diluted Shares Outstanding | 6.37M | 5.20M | 4.70M | 4.27M | 4.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |